Insulin glargine: Commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 1, 2004, Pages 1-3

  Rosenstock, Julio ^b,c   Owens, David ^a   McAulay, Vincent ^d   Frier, Brian ^d  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Dallas Diabetes and Endocrine Center   (United States)

^c LLANDOUGH HOSPITAL   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

CLINICAL TRIAL; DNA SYNTHESIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PAPILLEDEMA; RETINA NEOVASCULARIZATION; RISK ASSESSMENT; SINGLE DRUG DOSE; STEADY STATE;

CIRCADIAN RHYTHM; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0347916988     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.1.1     Document Type: Letter

References (16)

1. MCAULAY V, FRIER B: Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin. Pharmacotber. (2003) 4(7):1141-1156.
2. HAMANN A, MATTHAEI S, ROSAK C, SILVESTRE L: A randomized, clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with Type 1 diabetes. Diabetes Care (2003) 26(6):1738-1744.
3. FANELLI CG, PAMPANELLI S, PORCELLATI F et al.: Pharmacodynamics of subcutaneous injection of insulin glargine after the first as compared to seventh day of its once daily administration in patients with T1 DM. Diabetologia (2002) 45(Suppl. 2):A258.
4. ROSSETTI P. PAMPANELLI S, FANELLI C et al.: Intensive replacement of basal insulin in patients with Type 1 diabetes given rapid-acting insulin analog at mealtime. A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care (2003) 26(5):1490-1496.
5. RIDDLE M, ROSENSTOCK J: Treatment to target in Type 2 diabetes: successful glycaemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy. Diabetologia (2002) 45(Suppl. 2):A52.
6. ROSENSTOCK J, MASSI BENEDETTI M, HÄRING H, LIN Z, SALZMAN A: Confirmed lower risk of hypoglycaemia with insulin glargine versus NPH insulin: a metaanalysis of 2304 patients with Type 2 diabetes. Diabetologia (2003) 46(Suppl. 2):A304.
7. GARG S, HISATOMI M, HOFF H et al.: Impact of different insulin glargine regimens on glycemic parameters in intensively treated adults with Type 1 diabetes. Diabetologia (2003) 46(Suppl. 2):A273.
8. KURTZHALS P, SCHAFFER L, SORENSEN A et al.: Correlation of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use. Diabetes (2000) 49(6):999-1005.
9. CIARALDI T, CARTER L, SEIPKE G, MUDALIAR S, HENRY R: Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparison to insulin and IGF-1. J. Clin. Endocrinol. Metab. (2001) 86(12):5838-5847.
10. FORJANIC-KLAPPROTH J, HOME PD: Progression of retinopathy with insulin glargine or NPH insulin - a multi-trial analysis. Diabetologia (2001) 44(Suppl. 1):A287.
11. BOLLI GB, OWENS DR: Insulin glargine, a new long-acting insulin analogue soon to be available for the treatment of patients requiring insulin. Lancet (2000) 356(9228):443-445.
12. THRAILKILL KM, QUATTRIN T, BAKER L, KUNTZE JE, COMPTON PG, MARTHA PM Jr: Cotherapy with recombinant human insulin-like growth Factor I and insulin improves glycemic control in Type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care (1999) 22(4):585-592.
13. LEPORE M, PAMPANELLIS, FANELLI C et al: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes (2000) 49(12):2142-2148.
14. HEISE T, BOTTS, RAVE K, DRESSLER A, ROSSKAMP R, HEINEMANN L: No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. Diabet. Med. (2002) 19(6):490-495.
15. AMERICAN DIABETES ASSOCIATION: Standards of medical care for patients with diabetes mellitus. ADA position statement. Diabetes Care (2001) 24(Suppl. 1):S33-S43.
16. EUROPEAN DIABETES POLICY GROUP: A desktop guide to Type 2 diabetes mellitus. Diabet. Med. (1999) 16(9):716-730.